Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion (NCT07039461) | Clinical Trial Compass
TerminatedNot Applicable
Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion
Stopped: identification of several protocol deviations that may affect the primary outcome accuracy
United States4 participantsStarted 2025-09-12
Plain-language summary
To study the effectiveness and safety of IPL treatment for Chalazion
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subject is able to read, understand, and sign an Informed Consent Form (ICF)
* 18 years of age or older
* Clinical diagnosis of acute chalazion, present for a maximum of 4 weeks
* Subject is willing to comply with all study procedures
Exclusion Criteria:
* Subjects who underwent IPL treatment less than 6 months prior to screening
* Concurrent eyelid infection, which to the opinion of the study investigator is not related to the chalazion
* Chalazion with atypical features, which to the opinion of the study investigator is inadequate for a study
* Chronic Chalazion
* Recurring Chalazion
* Floppy eyelid syndrome
* Demodex blepharitis patients taking Lotilaner ophthalmic solution within 30 days prior to screening
* Ocular surgery within 3 months prior to screening
* Current diagnosis of malignant tumors in the affected eyelid, including: sebaceous carcinoma and basal cell carcinoma
* Laser Assisted In Situ Keratomileusis (LASIK)/Small Incision Lenticule Extraction (SMILE) surgery, within 1 year prior to screening
* Radial Keratotomy (RK) surgery
* Recent ocular trauma, within 3 months prior to screening
* Pre-cancerous lesions or skin cancer in the planned treatment area
* Severe active allergies, or other severe uncontrolled eye disorders affecting the ocular surface
* Uncontrolled infections or uncontrolled immunosuppressive diseases
* Best corrected visual acuity worse than 20/200 in either eye
* Ocular surface abnormality that may compromise corneal …
What they're measuring
1
The percentage of resolved chalazion 4 weeks after the last treatment in the study group and the control group